Sotera Health Co
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
SHC$16.27-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Operating activities: | |||
| Net income (loss) | $44,398 | $51,376 | $(233,570) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||
| Depreciation | 84,260 | 76,577 | 64,000 |
| Amortization of intangible assets | 79,377 | 81,348 | 81,554 |
| Loss on refinancing of debt | 24,168 | — | — |
| Impairment of investment in unconsolidated affiliate | — | — | 9,613 |
| Deferred income taxes | 9,433 | 3,449 | (73,960) |
| Share-based compensation expense | 36,777 | 32,238 | 21,211 |
| Accretion of asset retirement obligations | 2,638 | 2,413 | 2,194 |
| Unrealized foreign exchange (gain) loss | (18,337) | 6,057 | (3,984) |
| Unrealized loss (gain) on derivatives not designated as hedging instruments | 2,213 | (1,637) | 2,977 |
| Amortization of debt issuance costs | 7,238 | 9,051 | 5,681 |
| Other | (5,367) | (5,319) | (6,989) |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | 2,216 | (21,724) | (12,555) |
| Inventories | (4,753) | (9,972) | 14,441 |
| Other current assets | 3,598 | 4,003 | (5,816) |
| Accounts payable | (6,644) | (5,333) | 1,107 |
| Accrued liabilities | 7,114 | 3,500 | 20,595 |
| Illinois EO litigation settlement | — | (407,712) | 408,000 |
| Georgia EO litigation settlement | (35,000) | 35,000 | — |
| Income taxes payable / receivable, net | 1,470 | 924 | (12,332) |
| Other liabilities | (3,793) | (1,733) | 383 |
| Other long-term assets | (6,842) | (238) | (4,589) |
| Net cash provided by (used in) operating activities | 224,164 | (147,732) | 277,961 |
| Investing activities: | |||
| Purchases of property, plant and equipment | (179,070) | (214,975) | (182,378) |
| Purchase of Regulatory Compliance Associates Inc., net of cash acquired | — | — | 450 |
| Other investing activities | 74 | 69 | 32 |
| Net cash used in investing activities | (178,996) | (214,906) | (181,896) |
| Financing activities: | |||
| Proceeds from revolving credit facility and long-term borrowings | 2,259,350 | 500,000 | 200,000 |
| Payment of revolving credit facility | — | (200,000) | — |
| Payments of debt issuance costs and debt discount | (32,071) | (25,645) | (31) |
| Payments of long-term borrowings | (2,264,373) | (2,500) | — |
| Buyout of leased facility | (6,736) | — | — |
| Shares withheld for employee taxes on equity awards | (4,428) | (4,089) | (393) |
| Other financing activities | (2,306) | (1,807) | (1,815) |
| Net cash (used in) provided by financing activities | (50,564) | 265,959 | 197,761 |
| Effect of exchange rate changes on cash and cash equivalents | (17,393) | 2,039 | (4,456) |
| Net (decrease) increase in cash and cash equivalents, including restricted cash | (22,789) | (94,640) | 289,370 |
| Cash and cash equivalents, including restricted cash, at beginning of period | 301,654 | 396,294 | 106,924 |
| Cash and cash equivalents, including restricted cash, at end of period | $278,865 | $301,654 | $396,294 |
| Supplemental disclosures of cash flow information: | |||
| Cash paid during the period for interest | $179,924 | $173,842 | $75,849 |
| Cash paid during the period for income taxes, net of tax refunds received | 65,829 | 50,210 | 75,496 |
| Purchases of property, plant and equipment included in accounts payable | 10,180 | 16,720 | 16,413 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.